Diabetes Therapeutics Market Smart Strategies of the Research and Development Process

Pharmacological research is the most promising method to reduce the burden of type 2 diabetes globally. This has led to an increase in R&D activities in the diabetes drugs sector, which has resulted in the development of new variants of antidiabetic agents.

Global Diabetes Therapeutics Market was valued at $66,993 million in 2016, and is estimated to reach $186,842 million by 2023, growing at a CAGR of 16.0% from 2017 to 2023. Diabetes therapeutics are drugs used by diabetics to maintain the blood glucose levels to restore the blood glucose metabolism to a normal state. Diabetes therapeutics are drugs used by diabetic patients to conserve the blood glucose levels in the body.

Get the sample PDF copy @ https://www.alliedmarketresearch.com/request-sample/3542

The major factor that contributes to the market growth are increase in incidence rate of diabetes caused by rapid urbanization and sedentary lifestyle. Moreover, development of affordable & effective diabetes therapeutics, rise in obese population, consumption of fast food, growth in awareness among people about self-management of diabetes, and support from the government further boost the market growth. However, side effects of diabetic drugs on patients and stringent approval process for these drugs hinder this growth. Moreover, rise in awareness about diabetes care and untapped market opportunities in developing regions are expected to provide numerous opportunities for market growth.

The injectables segment is expected to maintain its dominant position during the analysis period, owing to rise in the prevalence of diabetes, increase in geriatric population, high demand of self-care, and increased awareness about use of insulin (one of the injectables) as an anti-diabetic drug.

Moreover, injectable can be used for both type-I and type-II diabetes, whereas OAD are used majorly for type-II diabetes. In addition, there is increased awareness about use of insulin (one of the injectable) as an anti-diabetic drug. Therefore, adoption of insulin is high in most of the regions of the world, which is expected to stimulate the growth of this segment.

Key Findings of the Diabetes Therapeutics Market

The injectables segment accounted for nearly two-thirds share of the global market in 2016.

GLP-1 receptor agonists segment expected to grow at a rapid CAGR of 33.1% from 2017 to 2023.

Insulin segment accounted for more than half of the global market in 2016.

Asia-Pacific is expected to grow at the highest CAGR of 16.8% from 2017 to 2023.

North America accounted for more than one-third share of the global market in 2016, and is expected to remain dominant throughout the forecast period. This is attributed to the increase in incidence of diabetes, growth in geriatric population, and adoption of sedentary lifestyle of people that leads to diabetes. In addition, presence of highly sophisticated healthcare infrastructure is expected to present new growth opportunities to the players in this market.

Do purchase inquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/3542

The major companies profiled in the report include AstraZeneca plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Key players in the value chain include Astellas Pharma Inc., Biocon Limited, Diasome Pharmaceuticals, Inc., Generex Biotechnology Corp., MannKind Corporation, and Pfizer Inc.

By Product

Injectables
Insulin
Glucagon-like Peptide-1 (GLP-1) Receptor Agonists/Incretin Mimetics
Amylin Analogue/Amylinomimetic Drugs
Oral-antidiabetic Drugs (OAD)
Biguanides
Sulfonylureas
Thiazolidinediones
Alpha-glucosidase Inhibitors
Dipeptidyl Peptidase IV (DPP-4) Inhibitors/Gliptins
Meglitinides
Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors/Gliflozins

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
Shriram Dighe
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.